Aclaris Therapeutics (ACRS) and The Competition Head-To-Head Analysis
Aclaris Therapeutics (NASDAQ: ACRS) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Aclaris Therapeutics to similar companies based on the strength of its risk, profitability, valuation, earnings, analyst recommendations, dividends and institutional ownership.
Volatility & Risk
Aclaris Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics’ peers have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.
This table compares Aclaris Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aclaris Therapeutics Competitors||-5,511.49%||-449.46%||-42.33%|
This is a breakdown of recent ratings and target prices for Aclaris Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aclaris Therapeutics Competitors||763||3032||11182||227||2.72|
Aclaris Therapeutics currently has a consensus target price of $41.25, indicating a potential upside of 62.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.50%. Given Aclaris Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Aclaris Therapeutics is more favorable than its peers.
Institutional & Insider Ownership
95.8% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.3% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Aclaris Therapeutics and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aclaris Therapeutics||N/A||-$49.56 million||-12.51|
|Aclaris Therapeutics Competitors||$260.16 million||$66.28 million||-6.61|
Aclaris Therapeutics’ peers have higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Aclaris Therapeutics beats its peers on 7 of the 12 factors compared.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.